Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retreatment with Iodine-131 Anti-B1 Antibody in NHL
NCT00938041Phase 2Completed
- Sponsor
- GSK
- Start
- Apr 1998
- Primary completion
- May 2003
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of tositumomab + iodine-131 tositumomab in non-Hodgkin lymphoma (NHL), sponsored by GSK. Primary endpoints: Number of Participants With Complete Response and Confirmed Complete Response at 2 years, Duration of Response for All Confirmed Responders at 2 years and 4 more. Started Apr 1998; status: completed.
02
Drugs
tositumomab + iodine-131 tositumomab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00938041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00938041.